Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.25 is 517% above its 4-year average of 0.04, near the high end of its 4-year range (0.00–0.25).
As of the fiscal period ended Tuesday, June 30, 2026. 101.41% above its 12-month average of 0.13.
Reported quarterly debt to equity ratio; no daily interpolation. Q3 FY2026 (2026-06-30): 0.25.
DEBT TO EQUITY RATIO
0.25
DEBT TO EQUITY RATIO AVG TTM
0.13
DEBT TO EQUITY RATIO AVG 3Y
0.07
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+101.41%
CURRENT VS 3Y AVG
+261.72%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 467 covered companies
CURRENT VS SECTOR MEDIAN
+80.59%
vs the sector median at left
Citius Oncology, Inc.
Market Cap
$79.59M
Debt to Equity Ratio
0.25
TTM Avg
0.13
3Y Avg
0.07
5Y Avg
N/A
Market Cap
$80.15M
Debt to Equity Ratio
1.83
TTM Avg
0.28
3Y Avg
0.24
5Y Avg
0.19
Market Cap
$77.06M
Debt to Equity Ratio
0.50
TTM Avg
0.43
3Y Avg
0.38
5Y Avg
0.27
Market Cap
$84.40M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$84.61M
Debt to Equity Ratio
N/A
TTM Avg
0.33
3Y Avg
0.19
5Y Avg
0.13
Market Cap
$72.51M
Debt to Equity Ratio
0.05
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.09
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | $79.59M | 0.25 | 0.13 | 0.07 | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $80.15M | 1.83 | 0.28 | 0.24 | 0.19 |
| MindWalk Holdings Corp. (HYFT)vs › | $77.06M | 0.50 | 0.43 | 0.38 | 0.27 |
| Hyperfine, Inc. (HYPR)vs › | $75.89M | 0.36 | 0.01 | 0.01 | 0.00 |
| LENSAR Inc (LNSR)vs › | $83.92M | 0.16 | 0.10 | 0.08 | 0.08 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.40M | 0.02 | 0.03 | 0.04 | 0.03 |
| Humacyte, Inc. (HUMA)vs › | $84.55M | 2.12 | 20.86 | 8.51 | 5.27 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.61M | N/A | 0.33 | 0.19 | 0.13 |
| Gain Therapeutics, Inc. (GANX)vs › | $72.51M | 0.05 | 0.07 | 0.07 | 0.09 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | 0.02 | 0.02 | 0.03 | 0.03 |
Debt/Equity
0.25
Current Ratio
0.73
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.25 |
| 2026-03-31 | 0.11 |
| 2025-12-31 | 0.07 |
| 2025-09-30 | 0.08 |
| 2025-06-30 | 0.12 |
| 2025-03-31 | 0.11 |
| 2024-12-31 | 0.09 |
| 2024-09-30 | 0.08 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
